Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Participants who required surgical incision and drainage after the treatment period or seven days after diagnosis · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Participants experiencing the occurrence of a chalazion after the treatment period or seven days after diagnosis · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Participants experiencing the recurrence of a hordeolum within six months and one year · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Participants with a secondary hordeolum during or after the treatment period and seven days after diagnosis · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · people with acute hordeolum
The review found no eligible studies for this question.
1 finding from 1 review
Number of infants with abnormal neurological signs · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Bilirubin (µmol/L) · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Rate of change in bilirubin (μmol/L/hour): during the first 4 hours of admission · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Control of bleeding (cure or improvement to acceptable level) At 2 years · women with heavy menstrual bleeding
Surgery probably leads to higher control of bleeding (cure or improvement to acceptable level) At 4… compared with oral medication (moderate certainty).
3 findings from 1 review
RR 2.66 [1.94, 3.64]
1 study · 186 participants
Moderate
RR 1.29 [1.06, 1.57]
1 study · 173 participants
Low
RR 1.14 [0.97, 1.34]
1 study · 140 participants
Very low
Overall satisfaction with treatment At 2 years · women with heavy menstrual bleeding
Surgery probably leads to higher overall satisfaction with treatment At 2 years compared with oral medication (moderate certainty).
1 finding from 1 review
Overall satisfaction with treatment At 5 years · women with heavy menstrual bleeding
It is very uncertain whether surgery changes overall satisfaction with treatment At 5 years compared with oral medication (very low certainty).
1 finding from 1 review
Adverse events at 4 months · women with heavy menstrual bleeding
Surgery probably leads to lower adverse events at 4 months compared with oral medication (moderate certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review